2024
Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country
Awidi A, Alzu'bi M, Odeh N, Alrawabdeh J, Al Zyoud M, Hamadneh Y, Bawa'neh H, Magableh A, Alshorman A, Al-Fararjeh F, Aladily T, Zeidan A. Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country. JCO Global Oncology 2024, 10: e2300281. PMID: 38422464, PMCID: PMC10914245, DOI: 10.1200/go.23.00281.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeAML transformationMDS/myeloproliferative neoplasmRevised International Prognostic Scoring SystemClonal bone marrow disordersRisk of AML transformationInternational Prognostic Scoring SystemBaseline serum ferritin levelsMultivariate Cox regression modelMale to female ratioMyelodysplastic syndromes/myeloproliferative neoplasmsPrimary myelodysplastic syndromesPrognostic scoring systemSerum ferritin levelsMyelodysplastic syndrome subtypesBaseline serum ferritinBone marrow disordersLactate dehydrogenase levelsCox regression modelsJordan University HospitalRetrospective registry dataRisk of deathPeripheral cytopeniasBaseline ferritinIneffective hematopoiesis
2021
Preoperative MRI and LDH in women undergoing intra-abdominal surgery for fibroids: Effect on surgical route
Kim A, Boyd L, Ringel N, Meyer J, Bennett G, Lerner V. Preoperative MRI and LDH in women undergoing intra-abdominal surgery for fibroids: Effect on surgical route. PLOS ONE 2021, 16: e0246807. PMID: 33561167, PMCID: PMC7872248, DOI: 10.1371/journal.pone.0246807.Peer-Reviewed Original ResearchConceptsAbnormal magnetic resonance imagingMagnetic resonance imaging resultsIntra-abdominal surgeryMagnetic resonance imagingPower morcellationSurgical routeAbnormal magnetic resonance imaging resultsOpen approachResonance imagingSerum lactate dehydrogenase levelPost-protocol groupPre-protocol groupRetrospective cohort studyBaseline patient characteristicsSubset of womenPost-menopausal womenLactate dehydrogenase levelsHigh-risk casesPreoperative magnetic resonanceDiffusion-weighted imagingHigh rateImaging resultsSymptomatic fibroidsChart reviewCohort study
2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
Hodi FS, Chapman PB, Sznol M, Lao CD, Gonzalez R, Smylie M, Daniels GA, Thompson JA, Kudchadkar R, Sharfman W, Atkins M, Spigel DR, Pavlick A, Monzon J, Kim KB, Ernst S, Khushalani NI, van Dijck W, Lobo M, Hogg D. Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Research 2020, 31: 67-75. PMID: 33234846, PMCID: PMC7757740, DOI: 10.1097/cmr.0000000000000708.Peer-Reviewed Original ResearchConceptsAdvanced melanomaEastern Cooperative Oncology Group performance statusUnresectable stage III/IV melanomaStage III/IV melanomaTreatment-related adverse eventsElevated lactate dehydrogenase levelBRAF wild-type tumorsOverall survival dataRandomized clinical trialsLactate dehydrogenase levelsAccess programBRAF-mutant tumorsRelevant patient subgroupsWild-type tumorsCombination nivolumabEligible patientsOS ratesCheckpoint inhibitorsTreatment discontinuationAdverse eventsPerformance statusUnacceptable toxicityMucosal melanomaPatient subgroupsClinical trialsAKI in Hospitalized Patients with and without COVID-19: A Comparison Study
Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns T, Abramowitz M, Levy R, Kumar N, Mokrzycki M, Coco M, Dominguez M, Prudhvi K, Golestaneh L. AKI in Hospitalized Patients with and without COVID-19: A Comparison Study. Journal Of The American Society Of Nephrology 2020, 31: asn.2020040509. PMID: 32669322, PMCID: PMC7461660, DOI: 10.1681/asn.2020040509.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAdultAgedAged, 80 and overBetacoronavirusCoronavirus InfectionsCOVID-19FemaleHospital MortalityHospitalizationHumansIncidenceIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisRenal Replacement TherapyResource AllocationRespiration, ArtificialRetrospective StudiesSARS-CoV-2ConceptsDevelopment of AKIMale sexAKI incidenceSevere AKIHistorical cohortIncidence of severe AKIBlack raceHospitalized patientsAssociated with male sexWhite blood cell countCenters treating patientsLactate dehydrogenase levelsRetrospective observational studyInitial respiratory rateBlood cell countStage 2Neutrophil/lymphocyte ratioRisk stratificationDehydrogenase levelsComposite outcomeAKI riskKidney functionCOVID-19 statusPatientsRisk factors
2018
Hemolytic Anemia and Gastric Carcinoid in a Russian Seafarer: Highlighting the Role of Diagnostic Technologies in Modern Clinical Practice.
Chaunzwa TL, O'Shea J, Boggs NA, Schwartz JI, Gibson J, Gielissen KA. Hemolytic Anemia and Gastric Carcinoid in a Russian Seafarer: Highlighting the Role of Diagnostic Technologies in Modern Clinical Practice. The Yale Journal Of Biology And Medicine 2018, 91: 243-246. PMID: 30258311, PMCID: PMC6153615.Peer-Reviewed Case Reports and Technical NotesConceptsAutoimmune gastritisNeurologic functionGastric carcinoidsPernicious anemiaHemolytic anemiaElevated lactate dehydrogenase levelMicroangiopathic hemolytic anemiaGastric carcinoid tumorsLactate dehydrogenase levelsNormal neurologic functionDifferent medical specialistsModern clinical practiceHealth insurance providersMicroangiopathic anemiaRepeat endoscopyAtypical presentationCarcinoid tumorsEndoscopic biopsyMapping biopsyTumor burdenIntramedullary hemolysisLow haptoglobinDehydrogenase levelsOccupational exposureReticulocyte count
2017
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal Of Clinical Oncology 2017, 36: jco.2016.71.802. PMID: 28671856, PMCID: PMC6804912, DOI: 10.1200/jco.2016.71.8023.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarboplatinDacarbazineDisease ProgressionDrug Administration ScheduleFemaleHumansMaleMelanomaMiddle AgedNivolumabPaclitaxelProgression-Free SurvivalSkin NeoplasmsTime FactorsYoung AdultConceptsInvestigator-choice chemotherapyAdvanced melanomaAnti-programmed death-1 (PD-1) agentsOpen-label phase III trialMedian progression-free survivalResults Two hundred seventyTreatment-related adverse eventsIpilimumab-refractory patientsNivolumab-treated patientsPhase III trialsProgression-free survivalProportion of patientsPoor prognostic factorOverall response rateLactate dehydrogenase levelsSurvival end pointsConclusion NivolumabMedian OSNivolumab groupBrain metastasesChemotherapy regimensUnacceptable toxicityAdverse eventsDurable responsesIII trials
2010
Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma
Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY. Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma. Cancer Investigation 2010, 29: 49-55. PMID: 21166498, DOI: 10.3109/07357907.2010.535052.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationOverall survivalCutaneous melanoma metastaticExtrahepatic metastatic sitesHepatic arterial chemoembolizationMedian overall survivalLactate dehydrogenase levelsType of treatmentMelanoma metastaticRadiologic responseDisease stabilizationLiver metastasesMost patientsPatient ageArterial chemoembolizationPrognostic factorsLiver diseaseMetastatic sitesCutaneous melanomaMedical recordsDehydrogenase levelsPatientsSignificant predictorsChemoembolizationSurvivalHepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver
Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P. Hepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver. American Journal Of Clinical Oncology 2010, 33: 474-480. PMID: 19935383, DOI: 10.1097/coc.0b013e3181b4b065.Peer-Reviewed Original ResearchConceptsHepatic arterial chemoembolizationOcular melanoma metastaticProgression-free survival durationMedian OS durationOverall survivalLactate dehydrogenase levelsMelanoma metastaticRadiologic responseLiver involvementSurvival durationOS durationDehydrogenase levelsResponse rateBaseline lactate dehydrogenase levelsHigher lactate dehydrogenase levelsMedian overall survivalTumor response rateHepatic artery chemoembolizationShorter overall survivalStable diseaseDisease stabilizationProgressive diseaseArterial chemoembolizationMost patientsPartial response
1997
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo D, Glatstein E, Duffey P, Young R, Ihde D, Bastian A, Wilson W, Wittes R, Jaffe E, Hubbard S, DeVita V. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Journal Of Clinical Oncology 1997, 15: 3338-46. PMID: 9363863, DOI: 10.1200/jco.1997.15.11.3338.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedPrednisoneProcarbazineProspective StudiesTreatment OutcomeVinblastineVincristineConceptsMantle field radiation therapyDisease-free survivalLarge mediastinal massMediastinal Hodgkin's diseaseHodgkin's diseaseABVD chemotherapyRadiation therapyOverall survivalMediastinal massMOPP/ABVDSecond solid tumorsTreatment-related pneumonitisComplete response rateAnn Arbor stageClinical prognostic factorsErythrocyte sedimentation rateTreatment of patientsAge 35 yearsLactate dehydrogenase levelsABVD therapyDacarbazine (ABVD) chemotherapyMedian followMOPP chemotherapySalvage therapyB symptoms
1984
Prolonged initial remission in patients with nodular mixed lymphoma.
Longo D, Young R, Hubbard S, Wesley M, Fisher R, Jaffe E, Berard C, DeVita V. Prolonged initial remission in patients with nodular mixed lymphoma. Annals Of Internal Medicine 1984, 100: 651-6. PMID: 6370065, DOI: 10.7326/0003-4819-100-5-651.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideFemaleHumansLeucovorinLymphoma, FollicularMaleMechlorethamineMethotrexateMiddle AgedNeoplasm StagingPrednisoneProcarbazinePrognosisRetrospective StudiesTime FactorsVincristineConceptsNodular mixed lymphomaComplete response rateMixed lymphomaComplete respondersInitial remissionMedian survivalResponse rateOverall complete response ratePrimary treatment regimensBone marrow involvementLactate dehydrogenase levelsNational Cancer InstituteAverage remissionB symptomsComplete remissionFirst remissionMarrow involvementShorter survivalTreatment regimensDehydrogenase levelsRemissionPatientsStage ICancer InstituteLymphoma
1981
Influence of prognostic factors on survival in Ewing's sarcoma.
Glaubiger D, Makuch R, Schwarz J. Influence of prognostic factors on survival in Ewing's sarcoma. National Cancer Institute Monograph 1981, 285-8. PMID: 7300894.Peer-Reviewed Original ResearchConceptsPrimary diseaseEwing's sarcomaTreatment groupsSerum lactate dehydrogenase levelIntensive adjuvant chemotherapySystemic chemotherapy regimensLactate dehydrogenase levelsNumber of patientsSignificant differencesNational Cancer InstituteRecent treatment regimensAdjuvant chemotherapyChemotherapy regimensPrognostic factorsPrimary lesionTreatment regimensLDH levelsMetastatic statusSurvival resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer InstituteSarcomaPrimary site
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply